MA48863B1 - TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES - Google Patents

TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES

Info

Publication number
MA48863B1
MA48863B1 MA48863A MA48863A MA48863B1 MA 48863 B1 MA48863 B1 MA 48863B1 MA 48863 A MA48863 A MA 48863A MA 48863 A MA48863 A MA 48863A MA 48863 B1 MA48863 B1 MA 48863B1
Authority
MA
Morocco
Prior art keywords
tgf
fusion proteins
receptor type
beta receptor
related uses
Prior art date
Application number
MA48863A
Other languages
French (fr)
Other versions
MA48863A (en
Inventor
Ravindra Kumar
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority claimed from PCT/US2018/030816 external-priority patent/WO2018204594A1/en
Publication of MA48863A publication Critical patent/MA48863A/en
Publication of MA48863B1 publication Critical patent/MA48863B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, selon certains aspects, des polypeptides de fusion ?ßr?? Comprenant une partie hétérologue et une partie tronquée de liaison à un ligand du domaine extracellulaire du polypeptide ?ßr??, utiles pour antagoniser de manière sélective un ligand ?ßr??. L'invention concerne également des compositions et des procédés destinées à être utilisés pour traiter ou prévenir des troubles associés au tgfß.Certain aspects of the present invention relate to ?ßr?? fusion polypeptides. Comprising a heterologous portion and a truncated ligand-binding portion of the extracellular domain of the ?ßr?? polypeptide, useful for selectively antagonizing a ?ßr?? ligand. Also provided are compositions and methods for use in treating or preventing disorders associated with tgfß.

MA48863A 2017-05-04 2018-05-03 TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES MA48863B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501229P 2017-05-04 2017-05-04
PCT/US2018/030816 WO2018204594A1 (en) 2017-05-04 2018-05-03 Tgf-beta receptor type ii fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
MA48863A MA48863A (en) 2020-04-01
MA48863B1 true MA48863B1 (en) 2023-08-31

Family

ID=88016828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48863A MA48863B1 (en) 2017-05-04 2018-05-03 TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES

Country Status (1)

Country Link
MA (1) MA48863B1 (en)

Also Published As

Publication number Publication date
MA48863A (en) 2020-04-01

Similar Documents

Publication Publication Date Title
MA34802B1 (en) NEW ANTIGEN
MA42622B1 (en) LIAISONS IN TIGIT AND THEIR USES
EP4241848A3 (en) Tgf-beta receptor type ii fusion proteins and uses thereof
MA39061A1 (en) Aplnr modulators and their uses
PE20191551A1 (en) DESIGNED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
MA40094B1 (en) Interleukin-2/interleukin-2 alpha receptor fusion proteins and methods of use
AR099079A1 (en) FC REGIONAL VARIANTS WITH MODIFIED FCRN UNION PROPERTIES
WO2021041715A3 (en) Compositions including igg fc mutations and uses thereof
SG10201908259WA (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
PE20090359A1 (en) POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS
AU2001228212A1 (en) Beta-turn peptidomimetic cyclic compounds
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
EA201201047A1 (en) METHODS AND COMPOSITIONS IN WHICH APPLY FGF 23 POLYPEPTIDES
EP4324481A3 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MA44334A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
RU2014153099A (en) THERAPEUTIC OR PREVENTIVE AGAINST DEMENTIA
MA39254B2 (en) Aggregating and high affinity stable antibodies based on vl viral domains and vhh derivative
MX2010004660A (en) NEW ANTIBODIES SPECIFIC OF THE beta-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS.
TW200636242A (en) Methods of modulating the activities of α7 nicotinic acetylcholine receptor
BRPI0507019A (en) composition, antibody use, antibody, msrv / herv-w env-su use
WO2021189010A8 (en) Methods of using activin receptor type iib variants
DE602007009803D1 (en) POLYPEPTIDES RECOGNIZED BY ANTI-TRICHINELLA ANTIBODIES AND THEIR USE
MX2012001278A (en) Anti - tgf - beta receptor type ii single domain antibodies.
MA48863B1 (en) TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND RELATED USES